Refund Policy Per Company Terms: According to the published refund policy, customers may return products within 30 days of delivery if they are unsatisfied, provided the products are returned in their original condition
Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes
Wegovy should not be used in combination with other GLP-1 receptor agonists
[20] [21] Seek urgent medical advice if you are already taking a GLP-1 medication and experience: Severe, persistent abdominal pain (possible pancreatitis) A new lump in your neck or changes in your voice Symptoms of severe hypoglycaemia (if taking other diabetes medications) Signs of thyroid dysfunction despite stable levothyroxine therapy Persistent vomiting leading to dehydration or inability to take oral medications Severe right upper abdominal pain, fever or jaundice (possible gallbladder disease) Open communication with your healthcare team ensures that treatment decisions are individualised, evidence-based, and aligned with your health priorities
Starred Row Callout: The Standard Retatrutide Setup The most common compounding setup for retatrutide is a 10mg vial with 2mL of BAC water